Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-03-30
1997-12-16
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 930144, C07K 14435, C07K 14525
Patent
active
056985185
ABSTRACT:
A method of treating patients to inhibit inflammation is disclosed. In the method, an effective amount of calmodulin, a calmodulin analogue or calmodulin receptor agonist is administered to a patient to inhibit production of tumor necrosis factor and/or augment elastase. In another method, an effective amount of calmodulin antagonist is administered to a patient to stimulate immune response or inhibit elastase release. In another embodiment, a diagnostic test is disclosed to be used on patient blood samples to determine individual propensity to regulate tumor necrosis factor and/or elastase by calmodulin, its analogues or receptor agonists.
REFERENCES:
patent: 4758559 (1988-07-01), Wasley
patent: 4965271 (1990-10-01), Mandell
patent: 5034395 (1991-07-01), Tamada
patent: 5096906 (1992-03-01), Mandell
patent: 5137889 (1992-08-01), Tamada
Tian et al., "Inhibitory Effects of PKC and CAM on TNF Production," Acta Pharma Sin, v. 14, n. 5, pp. 447-449 (1993).
Chan et al., "Calmodulin Inhibitor inhibits TNF Induced Neutrophil Chemilun"Am. Rev. Resp. Dis., v. 141, n. 4, p. 4919 (1990).
Aderka, et al., "1L-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice," J Immunology 143:3517-3523 (1989).
Boynton, et al., "Calmodulin stimulates DNA synthesis by rat liver cells," Biochem Biophys Research Communications 95:745-749 (1980).
Carson, et al., "Inducible release of an endothelial cell-specific protein, " Am J Pathol 139:199-206 (1991).
Chantry, et al., "Modulation of cytokine production by transforming growth factor-.beta.," J Immunology 142:4295-4300 (1989).
Cheung, W.Y. "Calmodulin plays a pivotal roll in cellular regulation," Science 207:19-27 (1980).
Crocker, et al., "An extracellular role for calmodulin-like activity in cell proliferation," Biochem J 253:877-844 (1988).
Dawson, et al., "Mitogenic role for extracellular calmodulin-like activity in normal human umbilical vein endothelial cells, " British J Haematology 82:151-160 (1992).
Dedman, et al., "Calmodulin purification and flourescent labeling," Methods in Enzymology 102:1-9 (1983).
Essner, et al., "IL-4 down-regulates IL-1 and TNF gene expression in human monocytes," J Immunology 142:3857-3861 (1989).
Fiorentino, et al., "IL-10 inhibits cytokine production by activated macrophages," J Immunology 147:3815-3822 (1991).
Goberdhan, et al., "A calmodulin-like protein as an extracellular mitogen for the keratinocyte," British J Dermatology 129:678-688 (1993).
Grundmann, et al., "Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication," J Infect Diseases 165:501-505 (1992).
Hampton, et al., "Recognition and plasma clearance of endotoxin by scavenger receptors," Nature 352:342-344 (1991).
Hart, et al., "IL-4 suppresses IL-1.beta., TNF-.alpha. and PGE.sub.2 production by human peritoneal macrophages," Immunology 72:344-349 (1991).
Ikezawa, et al., "Phosphatidylinositol-specific phospholipase C from Bacillus cereus and Bacillus thuringiensis," Methods of Enzymology 71:731-741 (1981).
Moore, et al., "Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro," J Clin Invest 79:124-130 (1987).
Ryan, et al., "Kinins, endothelial cells and calmodulin," Adv Exp Med Biol 156:671-679 (1983).
Schindler, et al., "Correlations and interactions in the production of Interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF," Blood 75:40-47 (1990).
Kunkel, et al., "Regulation of macrophage tumor necrosis factor production by prostaglandin E.sub.2, " Biochem Biophys Research Communications 137:404-410 (1986).
Mac Neil, et al., "Effects of extracellular calmodulin antagonists on B16 melanoma cell growth," J Invest Dermatology 83:15-19 (1984).
Means, et al., "Calmodulin-an intracellular calcium receptor," Nature 285:73-77 (1980).
le Vraux, et al., "Inhibition of human moncyte TNF production by adenosine receptor agonists." Life Sciences 52:1917-1924(1993).
Yui, et al., "Augmentation and suppression of TNF release from macrophages by inflammatory polymorphonuclear leukocytes," Microbiol Immunol 37:801-808 (1993).
Means, et al., "Regulatory functions of calmodulin," Pharmac Ther 50:255-270 (1991).
Minty, et al., "Interleukin-13 in a new human lymphokine regulating inflammatory and immune responses," Nature 362:248-250 (1993).
Moore, et al. "Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothlial cells in culture," Blood 73:159-165 (1989).
Carson Craig W.
Esmon Charles T.
Houston Donald S.
Delaney Patrick R.
Oklahoma Medical Research Foundation
Tsang Cecilia J.
LandOfFree
Method for regulating inflammation and tumor growth with calmodu does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for regulating inflammation and tumor growth with calmodu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for regulating inflammation and tumor growth with calmodu will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-205969